CLIMATE
VEGF Receptor Antibody, KDR 2.6
About
The KDR 2.6 clone is characterized by its ability to recognize the active/ligand-bound form of VEGFR-2.
In this aspect;
- Cell surface activation measurements by flow cytometry,
- Tumor microvasculature analysis by IF/IHC,
- Anti-angiogenic agent efficacy tests,
to provide highly accurate data.
It allows the mechanisms of tumor angiogenesis to be studied at a dynamic and functional level.
Product Overview
Recombinant antibody (ScFv) with potential for use in the treatment of Cancer Patients.
Product Name
VEGF Receptor Antibody, KDR 2.6
Product Short/Code Name
KDR 2.6
Product Type
Prototype Product
Developer Research Groups
Biotechnology Research Group
Production and Technology Status
Technology Readiness Level (THS)
THS 4
Technical Specifications
Biotechnological Drug Candidate
Recombinant Antibody
- In cancer patients.
